Long-Term Ibrutinib Plus Venetoclax Data Demonstrate Durable, Strong Responses in R/R MCL - OncLive

Long-Term Ibrutinib Plus Venetoclax Data Demonstrate Durable, Strong Responses in R/R MCL  OncLive

The Paradox of Progress: Personalizing First-Line Therapy in CLL - Targeted Oncology

The Paradox of Progress: Personalizing First-Line Therapy in CLL  Targeted Oncology

Short-Course Venetoclax With Azacitidine Delivers High Response in HR-MDS - Hematology Advisor

Short-Course Venetoclax With Azacitidine Delivers High Response in HR-MDS  Hematology Advisor

Masterclass | Optimizing BTKi + BCL-2i combination therapy for patients with CLL - Lymphoma Hub

Masterclass | Optimizing BTKi + BCL-2i combination therapy for patients with CLL  Lymphoma Hub

Time-Limited Zanubrutinib Plus Venetoclax: MRD-Guided Outcomes from SEQUOIA Arm D - CancerNetwork

Time-Limited Zanubrutinib Plus Venetoclax: MRD-Guided Outcomes from SEQUOIA Arm D  CancerNetwork

Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute my...

Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia: a multicenter phase 2 trial  Nature

Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML - AJMC

Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML  AJMC

HMA/Venetoclax Is Superior to Intensive Chemo in Fit Patients With AML - Targeted Oncology

HMA/Venetoclax Is Superior to Intensive Chemo in Fit Patients With AML  Targeted Oncology

BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1 -rearranged acute myeloid leukemi...

BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1 -rearranged acute myeloid leukemia  Nature

Fixed-Duration Venetoclax Combos Show Noninferior PFS to Ibrutinib in CLL - CancerNetwork

Fixed-Duration Venetoclax Combos Show Noninferior PFS to Ibrutinib in CLL  CancerNetwork

MRD-guided treatment with ibrutinib + venetoclax: Updates from the FLAIR trial - Lymphoma Hub

MRD-guided treatment with ibrutinib + venetoclax: Updates from the FLAIR trial  Lymphoma Hub

Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid...

Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia  Nature

Zanubrutinib/Venetoclax Continues to Impress in Treatment-Naive CLL/SLL - Targeted Oncology

Zanubrutinib/Venetoclax Continues to Impress in Treatment-Naive CLL/SLL  Targeted Oncology

The combination of venetoclax with dimethyl fumarate synergistically induces apoptosis in AML cel...

The combination of venetoclax with dimethyl fumarate synergistically induces apoptosis in AML cells by disrupting mitochondrial integrity through ROS accumulation  Nature

Fixed-Duration Ibrutinib/Venetoclax Shows Durable Responses in CLL, Says Dr Ghia - Targeted Oncology

Fixed-Duration Ibrutinib/Venetoclax Shows Durable Responses in CLL, Says Dr Ghia  Targeted Oncology

Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsin...

Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsing after allogeneic HSCT | Bone Marrow Transplantation  Nature

Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase...

Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib  Nature

Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetocl...

Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetoclax plus hypomethylating agents: a real-world, multicentric study | Blood Cancer Journal  Nature

Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resista...

Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies | Leukemia  Nature

Digital twin models for predicting venetoclax and azacitidine-induced neutropenia in patients wit...

Digital twin models for predicting venetoclax and azacitidine-induced neutropenia in patients with acute myeloid leukemia  Nature

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidin...

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net  Nature

Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute pr...

Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia  Nature

Venetoclax Plus Azacitidine Misses OS End Point in Newly Diagnosed Higher-Risk MDS - OncLive

Venetoclax Plus Azacitidine Misses OS End Point in Newly Diagnosed Higher-Risk MDS  OncLive

Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a mul...

Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial  The Lancet

Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in A...

Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML  The ASCO Post

Venetoclax/Azacitidine Yields No OS Improvement in Intermediate/High Risk MDS - CancerNetwork

Venetoclax/Azacitidine Yields No OS Improvement in Intermediate/High Risk MDS  CancerNetwork

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified...

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model  Nature

Venetoclax “Should Be Avoided” in Unselected Myeloma Patients - Hematology Advisor

Venetoclax “Should Be Avoided” in Unselected Myeloma Patients  Hematology Advisor

Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML - OncLive

Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML  OncLive

The Evolving Role of Retreatment With Venetoclax-Based Regimens in CLL - OncLive

The Evolving Role of Retreatment With Venetoclax-Based Regimens in CLL  OncLive

Omacetaxine and Venetoclax Show Benefits in MDS, No Improvement in AML - Targeted Oncology

Omacetaxine and Venetoclax Show Benefits in MDS, No Improvement in AML  Targeted Oncology

Zanubrutinib/Venetoclax Demonstrates Robust Efficacy in CLL/SLL - CancerNetwork

Zanubrutinib/Venetoclax Demonstrates Robust Efficacy in CLL/SLL  CancerNetwork

Venetoclax Combo Achieves Mixed Results in Relapsed/Refractory Multiple Myeloma - CancerNetwork

Venetoclax Combo Achieves Mixed Results in Relapsed/Refractory Multiple Myeloma  CancerNetwork

Acalabrutinib/Venetoclax sNDA Under FDA Review for Previously Untreated CLL - OncLive

Acalabrutinib/Venetoclax sNDA Under FDA Review for Previously Untreated CLL  OncLive

Long-Term Data Support Venetoclax Plus Rituximab in Relapsed/Refractory CLL - OncLive

Long-Term Data Support Venetoclax Plus Rituximab in Relapsed/Refractory CLL  OncLive

RP2D Dose of Ziftomenib Yields High Response Rates in NPM1-Mutated AML - CancerNetwork

RP2D Dose of Ziftomenib Yields High Response Rates in NPM1-Mutated AML  CancerNetwork

Venetoclax-Enzalutamide Combination Shows Promising Safety and Preliminary Efficacy in mCRPC - On...

Venetoclax-Enzalutamide Combination Shows Promising Safety and Preliminary Efficacy in mCRPC  OncLive

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells - ...

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells  PR Newswire

Decitabine/Cedazuridine Plus Venetoclax sNDA Under FDA Review for Newly Diagnosed AML - OncLive

Decitabine/Cedazuridine Plus Venetoclax sNDA Under FDA Review for Newly Diagnosed AML  OncLive

Modified Venetoclax Dose Outperforms Standard Care in Unfit AML Patients - AJMC

Modified Venetoclax Dose Outperforms Standard Care in Unfit AML Patients  AJMC

Venetoclax resistance in preclinical KMT2A-rearranged acute lymphoblastic leukemia models is char...

Venetoclax resistance in preclinical KMT2A-rearranged acute lymphoblastic leukemia models is characterized by high inter- and intra-model heterogeneity  Nature

Venetoclax/Obinutuzumab Is a Cost-Effective Treatment Option for CLL - Targeted Oncology

Venetoclax/Obinutuzumab Is a Cost-Effective Treatment Option for CLL  Targeted Oncology

Nemtabrutinib With Venetoclax Shows Promising Activity in R/R CLL/SLL - OncLive

Nemtabrutinib With Venetoclax Shows Promising Activity in R/R CLL/SLL  OncLive

Late Addition of Obinutuzumab to Acalabrutinib/Venetoclax Maintains Responses, Boosts Safety in T...

Late Addition of Obinutuzumab to Acalabrutinib/Venetoclax Maintains Responses, Boosts Safety in Treatment-Naive CLL  OncLive

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML:...

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study  Nature

Venetoclax-Enhanced RBAC Shows Promise in High-Risk Mantle Cell Lymphoma - OncLive

Venetoclax-Enhanced RBAC Shows Promise in High-Risk Mantle Cell Lymphoma  OncLive

Treatment of Acute Myeloid Leukemia in Elderly Patients With Azacitidine–Venetoclax Combination i...

Treatment of Acute Myeloid Leukemia in Elderly Patients With Azacitidine–Venetoclax Combination in Developing Countries: A Single-Center Experience  Cureus

mTOR inhibition sensitizes T-ALL cells to Venetoclax through engagement of the integrated stress ...

mTOR inhibition sensitizes T-ALL cells to Venetoclax through engagement of the integrated stress response  Nature

Zanubrutinib Extends PFS vs Acalabrutinib Plus Venetoclax in Untreated, Low-Risk CLL - OncLive

Zanubrutinib Extends PFS vs Acalabrutinib Plus Venetoclax in Untreated, Low-Risk CLL  OncLive

What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with C...

What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with CLL?  Lymphoma Hub

Zanubrutinib Shows Superior PFS vs Venetoclax/Obinutuzumab in Indirect Comparison of Treatment-Na...

Zanubrutinib Shows Superior PFS vs Venetoclax/Obinutuzumab in Indirect Comparison of Treatment-Naive CLL  OncLive

Venetoclax Consolidation After BTKi Shows Promise in CLL - Targeted Oncology

Venetoclax Consolidation After BTKi Shows Promise in CLL  Targeted Oncology

Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk fo...

Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403  Nature

R )-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venet...

R )-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venetoclax-resistant AML through MCL-1 downregulation  Nature

Fixed-Duration Venetoclax (Venclexta) Matches Continuous Ibrutinib (Imbruvica) in Frontline CLL -...

Fixed-Duration Venetoclax (Venclexta) Matches Continuous Ibrutinib (Imbruvica) in Frontline CLL  Oncology News Central

After 5 Decades, Is Standard AML Treatment for Young and Fit Patients About to Change? - Oncology...

After 5 Decades, Is Standard AML Treatment for Young and Fit Patients About to Change?  Oncology News Central

Indirect Comparison Favors Zanubrutinib vs Venetoclax Combo in CLL/SLL - CancerNetwork

Indirect Comparison Favors Zanubrutinib vs Venetoclax Combo in CLL/SLL  CancerNetwork

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly d...

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients | Blood Cancer Journal  Nature

Venetoclax-Based Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia - The ASCO Post

Venetoclax-Based Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia  The ASCO Post

Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML - CancerNetwork

Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML  CancerNetwork

Venetoclax Plus Azacitidine Does Not Meet Primary End Point for OS in MDS Trial - Docwire News

Venetoclax Plus Azacitidine Does Not Meet Primary End Point for OS in MDS Trial  Docwire News

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML -...

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML  OncLive

Emerging Data Suggest Select Benefit for Venetoclax in MDS: Ivo Carre, PhD - AJMC

Emerging Data Suggest Select Benefit for Venetoclax in MDS: Ivo Carre, PhD  AJMC

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation fo...

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia  Nature

Dr Shadman on the Impetus for Assessing Zanubrutinib Plus Venetoclax in Previously Untreated CLL/...

Dr Shadman on the Impetus for Assessing Zanubrutinib Plus Venetoclax in Previously Untreated CLL/SLL  OncLive

Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-...

Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation  Frontiers

Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobuli...

Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis | Blood Cancer Journal  Nature

Case Report: FIA plus venetoclax in a patient on hemodialysis - Frontiers

Case Report: FIA plus venetoclax in a patient on hemodialysis  Frontiers

VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MD...

VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MDS  OncLive

Correction: Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with but...

Correction: Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate  Nature

Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemi...

Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia  Nature

‘Profound’ data show azacitidine plus venetoclax significantly benefits patients with AML - Healio

‘Profound’ data show azacitidine plus venetoclax significantly benefits patients with AML  Healio

Factors affecting response and resistance to venetoclax in acute myeloid leukemia - Frontiers

Factors affecting response and resistance to venetoclax in acute myeloid leukemia  Frontiers

Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leu...

Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial  The Lancet

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypometh...

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations | Blood Cancer Journal  Nature

Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia - The New England Jou...

Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia  The New England Journal of Medicine

Zanubrutinib/Venetoclax Yields Deep Responses in Treatment-Naive CLL Regardless of Del17p/TP53 Mu...

Zanubrutinib/Venetoclax Yields Deep Responses in Treatment-Naive CLL Regardless of Del17p/TP53 Mutational Status  OncLive

Enhancing venetoclax efficacy in leukemia through association with HDAC inhibitors - Nature

Enhancing venetoclax efficacy in leukemia through association with HDAC inhibitors  Nature

European Commission approves fixed-duration acalabrutinib + venetoclax ± obinutuzumab for adult p...

European Commission approves fixed-duration acalabrutinib + venetoclax ± obinutuzumab for adult patients with previously untreated CLL  Lymphoma Hub

First-Line Ibrutinib Plus Venetoclax Demonstrates Activity in Older Patients With MCL - OncLive

First-Line Ibrutinib Plus Venetoclax Demonstrates Activity in Older Patients With MCL  OncLive

In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Compar...

In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison  AJMC

Clinical Utility of Early Bone Marrow Biopsy During Venetoclax Plus Hypomethylating Agent Therapy...

Clinical Utility of Early Bone Marrow Biopsy During Venetoclax Plus Hypomethylating Agent Therapy in Acute Myeloid Leukemia  Cancer Therapy Advisor

Venetoclax Effective in Older Patients With CLL - AJMC

Venetoclax Effective in Older Patients With CLL  AJMC

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice pattern...

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes | Blood Cancer Journal  Nature

Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days - Blood Cancer Journal - Nature

Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days - Blood Cancer Journal  Nature

Final analysis of the GAIA/CLL13 trial: Venetoclax combinations vs chemoimmunotherapy in CLL - Ly...

Final analysis of the GAIA/CLL13 trial: Venetoclax combinations vs chemoimmunotherapy in CLL  Lymphoma Hub

Dr Arora on Azacitidine Plus Venetoclax and Gilteritinib in FLT3 Wild-Type AML - OncLive

Dr Arora on Azacitidine Plus Venetoclax and Gilteritinib in FLT3 Wild-Type AML  OncLive

Venetoclax and the Impact on Management of Older Patients With AML - AJMC

Venetoclax and the Impact on Management of Older Patients With AML  AJMC

Ibrutinib–Venetoclax Outperforms Ibrutinib Alone and FCR in Long-Term CLL - Pharmacy Times

Ibrutinib–Venetoclax Outperforms Ibrutinib Alone and FCR in Long-Term CLL  Pharmacy Times

Venetoclax Combo Shows High Efficacy, Manageable Safety in First-Line CLL and SLL - Targeted Onco...

Venetoclax Combo Shows High Efficacy, Manageable Safety in First-Line CLL and SLL  Targeted Oncology

COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results - AJMC

COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results  AJMC

Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax...

Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML  Nature

Real-World Data Highlight Feasibility of Venetoclax Plus Obinutuzumab In First-Line CLL With Como...

Real-World Data Highlight Feasibility of Venetoclax Plus Obinutuzumab In First-Line CLL With Comorbidities  OncLive

sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL - CancerNetwork

sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL  CancerNetwork

Higher Infection Risk With Venetoclax-Obinutuzumab vs Zanubrutinib in CLL/SLL - AJMC

Higher Infection Risk With Venetoclax-Obinutuzumab vs Zanubrutinib in CLL/SLL  AJMC

Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagno...

Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial  Nature

MRD-Guided Therapy With Ibrutinib/Venetoclax or Ibrutinib Alone in Chronic Lymphocytic Leukemia -...

MRD-Guided Therapy With Ibrutinib/Venetoclax or Ibrutinib Alone in Chronic Lymphocytic Leukemia  The ASCO Post

Study Evaluates Nurse-Led Venetoclax Ramp Up Program for Patients With CLL - Cancer Nursing Today

Study Evaluates Nurse-Led Venetoclax Ramp Up Program for Patients With CLL  Cancer Nursing Today

Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic ...

Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins | Cell Death & Differentiation  Nature

MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL - AJMC

MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL  AJMC